With a fervent dedication to combatting antibiotic resistance, Dr. Gorityala spearheads innovative research in the discovery of new antimicrobial technologies and antibiotic drugs.
Drawing from over two decades of experience in biotechnology research, Dr. Gorityala has held pivotal roles, including Scientist at CanAm Bioresearch Inc. and Research Associate at the University of Manitoba, Canada. His academic journey includes a Ph.D. in Chemical Sciences from Nanyang Technological University, Singapore, where his research on nanoparticle-based designations and glycosylation garnered international acclaim.
Throughout his career, Dr. Gorityala’s contributions have been instrumental in developing hybrid antibiotic adjuvants that overcome resistance in pathogens like Pseudomonas aeruginosa. His expertise has led to the publication of numerous scientific papers and book chapters, showcasing his profound impact on the field of antibacterial discovery.
Notably, Dr. Gorityala’s work has been featured in esteemed publications such as the Journal of American Chemical Society and Angewandte Chemie, as well as media outlets like CBC News and the Winnipeg Free Press. His commitment to innovation has earned him recognition from organizations like the American Council on Science and Health.
“As CTO of Polyamyna Nanotech Inc., Dr. Gorityala continues to drive research initiatives aimed at addressing global health challenges posed by multidrug-resistant bacteria.”